
James E Galvin MD MPH
Neurodegenerative
Professor of Integrated Medical Sciences and Associate Dean for Clinical Research at the Charles E. Schmidt College of Medicine. He is also Professor of Nursing at the Christine E. Lynn College of Nursing and Director of the Leon and Toby Cooperman Center for Alzheimer Disease and Memory Disorders at the Marcus Neuroscience Institute, Boca Raton Regional Hospital
Join to View Full Profile
7700 Camino RealSte 200Boca Raton, FL 33433
Phone+1 561-869-6808
Dr. Galvin is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Education & Training
- Saint Louis UniversityMPH, Epidemiology, e.g. Cum Laude, 2003 - 2005
- University of Pennsylvania Health SystemFellowship, Neurological Rehabilitation, 1996 - 1997
- Medical College of Pennsylvania/Hahnemann University1995 - 1996
- Sidney Kimmel Medical College at Thomas Jefferson University/TJUHResidency, Neurology, 1993 - 1995
- Hackensack Medical Center1992 - 1993
- Rutgers New Jersey Medical SchoolClass of 1992
- Rutgers UniversityMS, Nutrition, 1986 - 1988
- New York UniversityBA, Chemistry, 1982 - 1986
Certifications & Licensure
- FL State Medical License 2015 - 2027
- NY State Medical License 2010 - 2015
- MO State Medical License 2000 - 2011
- PA State Medical License 1994 - 2000
- NJ State Medical License 1993 - 1997
- American Board of Psychiatry and Neurology Neurology
Awards, Honors, & Recognition
- Junior Faculty Career Development Award National Palliative Care Research Center, 2012
- KL2 Clinical and Translational Research Award NYU-HHC Clinical and Translational Science Institute, 2012
- Outstanding Contributor Alzheimer Research Forum, 2008
- Join now to see all
Clinical Trials
- AC-1204 26-Week Long Term Efficacy Response Trial With Optional Open-label Ext Start of enrollment: 2013 Mar 01
- Fox BioNet Project: LRRK2-002 Start of enrollment: 2018 May 16
Publications & Presentations
PubMed
- Development and Validation of the DA3 Scale for Assessing Depression, Anxiety, and Apathy in Older Adults.Deirdre M O'Shea, Lun-Ching Chang, Gregory Gibbs, Conor B Galvin, Michael J Kleiman
The American Journal of Geriatric Psychiatry. 2025-03-08 - Cognivuecharacterizes amyloid status and preclinical Alzheimer's disease in biomarker confirmed cohorts in the Bio-Hermes Study.James E Galvin, Michael J Kleiman, Paul W Estes, Heather M Harris, Ernest Fung
Journal of Alzheimer's Disease. 2025-03-01 - The Dementia Literacy Assessment (DeLA): A novel measure of Alzheimer's disease and related disorders health literacy in diverse populations.James E Galvin, Deborah M Germain, Claudia P Moore, Jennifer A Jeanty, Vaatausili Tofaeono
Alzheimer's & Dementia. 2025-02-19
Journal Articles
- DOPAL, the MAO Metabolite of Dopamine is Responsible for Dopamine Neuron Loss and Triggers ?-Synuclein Aggregation in vitro.Burke WJ, Kumar VB, Pandey N, Franko MW, O’Dell M, Chung HD, and Galvin JE, Acta Neuropathologica
- Relationship of Cytotoxic Activity of Natural Killer Cells to Growth and Serum Zinc Levels of Female RIII Mice Fed Zinc.Bunk MJ, Galvin JE, Yung YP, Dnistrian AM, and Blaner WS, Nutr Can
- Increased Vulnerability of NFH-LacZ Transgenic Mouse to Traumatic Brain Injury-Induced Behavioral Deficits and Cortical Damage.84. Nakamura M, Saatman KE, Galvin JE, Scherbel U, Raghupathi R, Trojanowski JQ, McIntosh TK, J Cereb Blood Flow Metab
- Join now to see all
Books/Book Chapters
Press Mentions
- How to Lower Your Risk of Dementia Starting in Middle AgeFebruary 10th, 2025
- How to Drastically Reduce the Risk of Dementia After 55 Years of AgeFebruary 1st, 2025
- Cognition’s Positive Phase 2 ‘SHIMMER’ Study of Zervimesine (CT1812) in Dementia with Lewy Bodies (DLB) Will Be Presented in a Podium Presentation at ILBDCJanuary 30th, 2025
- Join now to see all
Grant Support
- Cross-disciplinary research opportunity for training in AD/ADRD science (CROSSROADS)UNIVERSITY OF MIAMI SCHOOL OF MEDICINE2024–2029
- IND enabling CMC/safety/toxicology studies, submission of IND and pilot Phase 1 clinical trial with PV-1950R vaccine for Lewy Body Dementia (LBD)INSTITUTE FOR MOLECULAR MEDICINE2024–2029
- Native Alzheimer Disease Resource Center for Minority Aging Research (NAD-RCMAR)UNIVERSITY OF MIAMI SCHOOL OF MEDICINE2018–2028
- Native Alzheimer Disease Resource Center for Minority Aging Research (NAD-RCMAR)UNIVERSITY OF MIAMI SCHOOL OF MEDICINE2018–2028
- Native Alzheimer Disease Resource Center for Minority Aging Research (NAD-RCMAR)UNIVERSITY OF MIAMI SCHOOL OF MEDICINE2018–2028
- Native Alzheimer Disease Resource Center for Minority Aging Research (NAD-RCMAR)UNIVERSITY OF MIAMI SCHOOL OF MEDICINE2018–2028
- Native Alzheimer Disease Resource Center for Minority Aging Research (NAD-RCMAR)UNIVERSITY OF MIAMI SCHOOL OF MEDICINE2018–2028
- Native Alzheimer Disease Resource Center for Minority Aging Research (NAD-RCMAR)UNIVERSITY OF MIAMI SCHOOL OF MEDICINE2018–2028
- Native Alzheimer Disease Resource Center for Minority Aging Research (NAD-RCMAR)UNIVERSITY OF MIAMI SCHOOL OF MEDICINE2018–2028
- Native Alzheimer Disease Resource Center for Minority Aging Research (NAD-RCMAR)UNIVERSITY OF MIAMI SCHOOL OF MEDICINE2018–2028
- Native Alzheimer Disease Resource Center for Minority Aging Research (NAD-RCMAR)UNIVERSITY OF MIAMI SCHOOL OF MEDICINE2018–2028
- A Phase 2b Clinical Study of the P38 Alpha Kinase Inhibitor Neflamapimod in Patients with Mild-to-Moderate Dementia with Lewy Bodies (DLB)EIP PHARMA, INC.2023–2026
- A Phase 2b Clinical Study of the P38 Alpha Kinase Inhibitor Neflamapimod in Patients with Mild-to-Moderate Dementia with Lewy Bodies (DLB)EIP PHARMA, INC.2023–2026
- A Phase 2b Clinical Study of the P38 Alpha Kinase Inhibitor Neflamapimod in Patients with Mild-to-Moderate Dementia with Lewy Bodies (DLB)EIP PHARMA, INC.2023–2026
- A Phase 2b Clinical Study of the P38 Alpha Kinase Inhibitor Neflamapimod in Patients with Mild-to-Moderate Dementia with Lewy Bodies (DLB)EIP PHARMA, INC.2023–2026
- A Phase 2b Clinical Study of the P38 Alpha Kinase Inhibitor Neflamapimod in Patients with Mild-to-Moderate Dementia with Lewy Bodies (DLB)EIP PHARMA, INC.2023–2026
- A Phase 2b Clinical Study of the P38 Alpha Kinase Inhibitor Neflamapimod in Patients with Mild-to-Moderate Dementia with Lewy Bodies (DLB)EIP PHARMA, INC.2023–2026
- A Phase 2b Clinical Study of the P38 Alpha Kinase Inhibitor Neflamapimod in Patients with Mild-to-Moderate Dementia with Lewy Bodies (DLB)EIP PHARMA, INC.2023–2026
- A Phase 2b Clinical Study of the P38 Alpha Kinase Inhibitor Neflamapimod in Patients with Mild-to-Moderate Dementia with Lewy Bodies (DLB)EIP PHARMA, INC.2023–2026
- A Phase 2b Clinical Study of the P38 Alpha Kinase Inhibitor Neflamapimod in Patients with Mild-to-Moderate Dementia with Lewy Bodies (DLB)EIP PHARMA, INC.2023–2026
- A Phase 2b Clinical Study of the P38 Alpha Kinase Inhibitor Neflamapimod in Patients with Mild-to-Moderate Dementia with Lewy Bodies (DLB)EIP PHARMA, INC.2023–2026
- A Phase 2b Clinical Study of the P38 Alpha Kinase Inhibitor Neflamapimod in Patients with Mild-to-Moderate Dementia with Lewy Bodies (DLB)EIP PHARMA, INC.2023–2026
- Natives Engaged in Alzheimer's ResearchWASHINGTON STATE UNIVERSITY2021–2026
- Natives Engaged in Alzheimer's ResearchWASHINGTON STATE UNIVERSITY2021–2026
- Natives Engaged in Alzheimer's ResearchWASHINGTON STATE UNIVERSITY2021–2026
- Natives Engaged in Alzheimer's ResearchWASHINGTON STATE UNIVERSITY2021–2026
- Natives Engaged in Alzheimer's ResearchWASHINGTON STATE UNIVERSITY2021–2026
- Multicultural Community Dementia ScreeningUNIVERSITY OF MIAMI SCHOOL OF MEDICINE2021–2026
- Natives Engaged in Alzheimer's ResearchWASHINGTON STATE UNIVERSITY2021–2026
- Natives Engaged in Alzheimer's ResearchWASHINGTON STATE UNIVERSITY2021–2026
- Natives Engaged in Alzheimer's ResearchWASHINGTON STATE UNIVERSITY2021–2026
- Natives Engaged in Alzheimer's ResearchWASHINGTON STATE UNIVERSITY2021–2026
- Natives Engaged in Alzheimer's ResearchWASHINGTON STATE UNIVERSITY2021–2026
- Natives Engaged in Alzheimer's ResearchWASHINGTON STATE UNIVERSITY2021–2026
- Deep Phenotypic Characterization of Prodromal Dementia with Lewy BodiesUNIVERSITY OF MIAMI SCHOOL OF MEDICINE2022–2025
- Alzheimer's Disease and Related Dementias (ADRD) prevalence in American SamoaAMERICAN SAMOA COMMUNITY CANCER COALITIO2022–2025
- A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Phase 2 Study to Evaluate the Safety and Efficacy of CT1812 in Subjects with Dementia with Lewy BodiesCOGNITION THERAPEUTICS, INC.2021–2025
- Digital Detection of Dementia Studies (D cubed Studies).INDIANA UNIVERSITY INDIANAPOLIS2020–2025
- Digital Detection of Dementia Studies (D cubed Studies).INDIANA UNIVERSITY INDIANAPOLIS2020–2025
- Digital Detection of Dementia Studies (D cubed Studies).INDIANA UNIVERSITY INDIANAPOLIS2020–2025
- Digital Detection of Dementia Studies (D cubed Studies).INDIANA UNIVERSITY INDIANAPOLIS2020–2025
- Digital Detection of Dementia Studies (D cubed Studies).INDIANA UNIVERSITY INDIANAPOLIS2020–2025
- Digital Detection of Dementia Studies (D cubed Studies).INDIANA UNIVERSITY INDIANAPOLIS2020–2025
- Reducing Disparities in Dementia and VCID Outcomes in a Multicultural Rural PopulationUNIVERSITY OF MIAMI SCHOOL OF MEDICINE2020–2025
- Digital Detection of Dementia Studies (D cubed Studies).INDIANA UNIVERSITY INDIANAPOLIS2020–2025
- Digital Detection of Dementia Studies (D cubed Studies).INDIANA UNIVERSITY INDIANAPOLIS2020–2025
- Digital Detection of Dementia Studies (D cubed Studies).INDIANA UNIVERSITY INDIANAPOLIS2020–2025
- The LUCINDA TrialWEILL MEDICAL COLL OF CORNELL UNIV2018–2025
- The LUCINDA TrialWEILL MEDICAL COLL OF CORNELL UNIV2018–2025
- The LUCINDA TrialWEILL MEDICAL COLL OF CORNELL UNIV2018–2025
- The LUCINDA TrialWEILL MEDICAL COLL OF CORNELL UNIV2018–2025
- The LUCINDA TrialWEILL MEDICAL COLL OF CORNELL UNIV2018–2025
- The LUCINDA TrialWEILL MEDICAL COLL OF CORNELL UNIV2018–2025
- The LUCINDA TrialWEILL MEDICAL COLL OF CORNELL UNIV2018–2025
- The LUCINDA TrialWEILL MEDICAL COLL OF CORNELL UNIV2018–2025
- The LUCINDA TrialWEILL MEDICAL COLL OF CORNELL UNIV2018–2025
- Education And Information Transfer CoreNational Institute On Aging2010–2012
- Multicultural Community Dementia Screening.National Institute On Aging2011
- Dementia Of Parkinson Type: Clinicopathologic PhenotypeNational Institute On Aging2002–2004
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence: